Corporate | 30 April 2010 17:40
Cytos Biotechnology AG / Change of Personnel
30.04.2010 17:40
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Schlieren (Zurich), Switzerland, April 30, 2010 - Cytos Biotechnology Ltd
(SIX:CYTN) announced that the longtime chief financial officer Jakob
Schlapbach wishes to make use of the option of early retirement from his
operational role.
The Board appointed Mr. Harry Welten as his successor. Harry Welten will
begin at 1 June 2010 and take over after a short familiarization phase the
role of CFO of Jakob Schlapbach.
Dr. Wolfgang Renner, CEO of Cytos Biotechnology: 'We thank Jakob Schlapbach
for his 10 years as CFO at Cytos Biotechnology. Jakob Schlapbach has done
all financial transactions since 2000, particularly the IPO, when Cytos
Biotechnology listed on the Swiss stock exchange after the acquisition of
Asklia Holding AG. We wish him all the best for the future and are pleased
that he will bring his experience to the Board of directors as a member.'
Harry Welten has many years of international professional and transaction
experience. Recently Harry Welten was CFO during the merger of the company
Nitec Pharma AG with the American firm Horizon Pharma AG. Previously, he
served for nine years at the company Arpida AG as CFO and was responsible
among other things, for the listing on the Swiss stock exchange in 2005.
Harry Welten: 'I am very happy that I can use my knowledge at Cytos
Biotechnology. I am convinced that I can bring my many years of experience
as a CFO in the life science industry and relationships with investors to
support Cytos Biotechnology.'
Dr. Wolfgang Renner: 'We are proud to have attracted Harry Welten, an
experienced financial expert with a long standing track record in the
biotech industry as a CFO. Harry, thanks to his previous activities as CFO
of Arpida AG and Nitec Pharma AG has a wide network of relationships with
investors and analysts. We welcome Harry Welten and wish him a good start.'
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 81 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'will', 'are intended for', 'are designed
to' or other similar expressions. These forward-looking statements are
subject to a variety of significant uncertainties, including scientific,
business, economic and financial factors, and therefore actual results may
differ significantly from those presented. There can be no assurance that
any further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments. This document does not constitute an offer
or invitation to subscribe or purchase any securities of Cytos
Biotechnology Ltd.
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Wagistrasse 25, Postfach
CH-8952 Schlieren (Zurich)
Tel. +41 44 733 47 03
Fax. +41 44 733 47 04
e-mail: wolfgang.renner@cytos.com
www.cytos.com
30.04.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
WKN: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in
Frankfurt; Foreign Exchange(s) SIX
End of News DGAP News-Service
---------------------------------------------------------------------------